4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Atara Biotherapeutics, Inc. (ATRA) operates in the Biotechnology industry and is headquartered in Thousand Oaks, United States with about 13 employees. Its market capitalization is roughly $71 million. In the fiscal year ended 2025-12-31, ATRA reported $121M in revenue and $33M in net income.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Interactive charts & full statements → Open the ATRA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $121M | $129M | $9M | $64M | — |
| Gross Profit | $100M | $108M | ($0M) | $64M | — |
| Operating Income (EBIT) | $36M | ($83M) | ($276M) | ($280M) | — |
| Net Income | $33M | ($85M) | ($276M) | ($228M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $2M | $4M | $18M | $98M | — |
| Gross Profit | $0M | $2M | $3M | $17M | $78M | — |
| Operating Income (EBIT) | ($3M) | ($3M) | ($4M) | $4M | $39M | — |
| Net Income | ($4M) | ($3M) | ($4M) | $2M | $38M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $20M | $109M | $166M | $376M | — |
| Total Liabilities | $59M | $206M | $265M | $250M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ATRA viewer.
About TickerBase · Data methodology & sources